ArticlePLoS pathogens2026
Evaluating beta-tubulin variants as predictors of benzimidazole resistance across Caenorhabditis nematodes.
Article in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Twenty Years of Benzimidazole Scaffold Optimization in Antiparasitic Drug Discovery.ChemMedChem · 2026Review
Corrections and comments
- Update of
Authors and funding
9 authors.
Funding
Abstract
Benzimidazoles, a widely used class of anthelmintic drugs, target beta-tubulin, disrupt microtubule formation, and delay nematode development. In parasitic nematodes, mutations in beta-tubulin genes are predicted to inhibit benzimidazole binding and are associated with resistance. In the free-living nematode Caenorhabditis elegans, loss-of-function mutations in the beta-tubulin gene ben-1 cause benzimidazole resistance. Although several beta-tubulin mutations serve as established markers of resistance, the prediction of the effects of novel variants in different nematode species remains challenging. Here, we identified novel beta-tubulin variants predicted to confer benzimidazole resistance across wild strains in three Caenorhabditis species: C. elegans, Caenorhabditis briggsae, and Caenorhabditis tropicalis. The three Caenorhabditis species are experimentally tractable, have characterized beta-tubulin gene complements, and defined natural niches, which allowed us to identify variants in beta-tubulin genes and test which variants are associated with resistance. We hypothesized that, if these species experienced similar selective pressures, they would evolve resistance to benzimidazoles by mutations in a beta-tubulin gene (tbb-1, tbb-2, mec-7, tbb-4, and ben-1). In the three Caenorhabditis species, we tested all strains harboring variants in the five conserved beta-tubulin genes for benzimidazole resistance. In C. elegans, we found that a heterogeneous set of variants in ben-1 were associated with resistance. By contrast, only two variants in C. briggsae ben-1 (W21stop and Q134H) were associated with resistance, suggesting selection acts differently in C. briggsae than in C. elegans despite overlapping geographic ranges between the two species. C. tropicalis was distinct from the other two species, where no strains with variants in any beta-tubulin gene were resistant. We generated deletions of ben-1 in C. briggsae and C. tropicalis and confirmed that loss of ben-1 confers resistance in both species. Our findings reveal species-specific patterns of beta-tubulin-mediated benzimidazole resistance and emphasize that prediction of variants in beta-tubulin genes alone is not sufficient to predict resistance, especially across diverse Caenorhabditis species.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.